MARKET

NGNE

NGNE

Neurogene
NASDAQ
42.59
+0.60
+1.43%
After Hours: 41.53 -1.06 -2.49% 17:21 06/14 EDT
OPEN
42.00
PREV CLOSE
41.99
HIGH
43.06
LOW
39.41
VOLUME
85.87K
TURNOVER
0
52 WEEK HIGH
53.00
52 WEEK LOW
3.050
MARKET CAP
552.83M
P/E (TTM)
-9.2926
1D
5D
1M
3M
1Y
5Y
Neurogene a new outperform at Baird on gene therapy for Rett syndrome
Seeking Alpha · 3d ago
Neurogene Price Target Announced at $54.00/Share by Baird
Dow Jones · 3d ago
Neurogene Initiated at Outperform by Baird
Dow Jones · 3d ago
Baird Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $54
Benzinga · 3d ago
Weekly Report: what happened at NGNE last week (0603-0607)?
Weekly Report · 4d ago
Neurogene to Participate in Upcoming Conferences
Neurogene management will participate in the following conferences. Neurogene is a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases. The company is developing treatments to address the limitations of conventional gene therapy in central nervous system disorders.
Barchart · 06/05 06:30
Neurogene (NGNE) Receives a Buy from TD Cowen
TipRanks · 06/04 11:35
Buy Rating Affirmed: Neurogene’s NGN-401 Poised for Strategic FDA Advancements and Positive Data Release
TipRanks · 06/04 10:25
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.